Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD

International Journal of COPD

Volumn 12, Issue , 2017, Pages 1819-1824

  Zysman, Maeva ^a   Deslee, Gaëtan ^b   Caillaud, Denis ^c   Chanez, Pascal ^d   Escamilla, Roger ^e   Court Fortune, Isabelle ^f   Nesme Meyer, Pascale ^g   Perez, Thierry ^h   Paillasseur, Jean Louis ⁱ   Pinet, Christophe ^j   Jebrak, Gilles ^k   Roche, Nicolas ^l   Burgel, Pierre Régis ^l  

^a INSERM U955   (France)

^b HÔPITAL MAISON BLANCHE   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e SERVICE DE PNEUMOLOGIE   (France)

^f UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^g CROIX ROUSSE HOSPITAL   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ EFFI STAT   (France)

^j Service de Pneumologie   (France)

^k BICHAT HOSPITAL   (France)

^l Institut Cochin   (France)

more..

Author keywords

COPD; Eosinophils; Exacerbations; Quality of life; Survival

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT;

ADULT; AGED; ARTICLE; ASTHMA; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DYSPNEA; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; MORTALITY RATE; OCCUPATIONAL EXPOSURE; PROGNOSIS; SMOKING; SPIROMETRY; SPUTUM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SURVIVAL RATE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; KAPLAN MEIER METHOD; LUNG; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHENOTYPE; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

AGED; BRONCHODILATOR AGENTS; COMORBIDITY; DISEASE PROGRESSION; EOSINOPHILS; FEMALE; FRANCE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG; MALE; MIDDLE AGED; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RISK FACTORS; SPIROMETRY; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 85021694030     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S129787     Document Type: Article

References (17)

1. Woodruff PG, Agusti A, Roche N, Singh D, Martinez FJ. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet. 2015;385(9979):1789–1798.
2. Hinds DR, DiSantostefano RL, Le HV, Pascoe S. Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis. BMJ Open. 2016;6(6): e010099.
3. Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax. 2016;71(2):118–125.
4. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193(9):965–974.
5. Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4): 523–525.
6. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–442.
7. Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016;47(5):1374–1382.
8. Bafadhel M, Davies L, Calverley PM, Aaron SD, Brightling CE, Pavord ID. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J. 2014;44(3):789–791.
9. Bafadhel M, Greening NJ, Harvey-Dunstan TC, et al. Blood eosinophils and outcomes in severe hospitalised exacerbations of COPD. Chest. 2016;150(2):320–328.
10. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23): 2222–2234.
11. Duman D, Aksoy E, Agca MC, et al. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia. Int J Chron Obstruct Pulmon Dis. 2015;10:2469–2478.
12. Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J. 2010;36(3):531–539.
13. Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–398.
14. DiSantostefano RL, Hinds D, Van Le H, Barnes NC. Relationship between blood eosinophils and clinical characteristics in a crosssectional study of a US population-based COPD cohort. Respir Med. 2016;112:88–96.
15. Caillaud D, Chanez P, Escamilla R, et al. Asthma-COPD overlap syndrome (acos) versus “pure” COPD: a distinct phenotype? Allergy. 2017; 72(1):137–145.
16. Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014; 44(6):1697–1700.
17. Keene JD, Jacobson S, Kechris K, et al; COPDGene and SPIROMICS Investigators. Biomarkers predictive of exacerbations in the SPIROMICS and COPDGene cohorts. Am J Respir Crit Care Med. 2017;195(4): 473–481.